Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.

ABSTRACT: We previously reported that synthetic vaccine particles (SVP) encapsulating antigens and TLR agonists resulted in augmentation of immune responses with minimal production of systemic inflammatory cytokines. Here we evaluated two different polymer formulations of SVP-encapsulated antigens and tested their ability to induce cytolytic T lymphocytes (CTL) in combination with SVP-encapsulated adjuvants. One formulation led to efficient antigen processing and cross-presentation, rapid and sustained CTL activity, and expansion of CD8+ T cell effector memory cells locally and centrally, which persisted for at least 1-2 years after a single immunization. SVP therapeutic dosing resulted in suppression of tumor growth and a substantial delay in mortality in several syngeneic mouse cancer models. Trea

SUBMITTER: Ilyinskii PO 

PROVIDER: S-EPMC5983463 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature